Articles

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
Medical Dept. 2, County Hospital, Steyr, Austria
Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
Department of Medicine, Hematology and Clinical Immunology Branch, University of Padua, Padua, Italy
Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Department of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria
NOXXON Pharma, Berlin, Germany
NOXXON Pharma, Berlin, Germany;current affiliation: Mologen AG, Berlin, Germany and
NOXXON Pharma, Berlin, Germany
NOXXON Pharma, Berlin, Germany;current affiliation: Mologen AG, Berlin, Germany and
NOXXON Pharma, Berlin, Germany
NOXXON Pharma, Berlin, Germany
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
Haematology Clinic, Department of Internal Medicine, University of Genoa, and Ospedale Policlinico S. Martino, Clinica Ematologica, Genoa, Italy
Vol. 104 No. 10 (2019): October, 2019 https://doi.org/10.3324/haematol.2018.205930